Gilead Sciences Inc at TD Cowen Healthcare Conference Transcript
Exciting. All right. Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference.
For our next session, it's a privilege to have a fireside chat with Gilead management. And from Gilead, it's my pleasure to introduce Johanna Mercier, Chief Commercial Officer of Gilead. Johanna, it's a privilege to have you here. Thank you very much for joining me.
Questions & Answers
So I figured I would start at a high level with the 2026 guidance. Can you walk us through the key assumptions to the guidance that you all issued and the primary levers, specifically as it pertains to product sales and earnings? Is that working?
So, our '26 guidance (technical difficulty)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
